Reading APLS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APLS free→Reading APLS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APLS free→QuarterlyIQ Insights · APLS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. CVR Agreement Pursuant to the Merger Agreement and in connection with the irrevocable acceptance for payment by Purchaser of all outstanding Shares validly tendered and not validly withdrawn pursuant to the Offer, on May 14, 2026, Biogen, the Company and Equiniti entered into the CVR Agreement. Each CVR represents a non-transferable contractual contingent right to receive the following cash payments, without interest and subject to reduction for any…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 13, 2026, the Company (i) notified The Nasdaq Stock Market (“Nasdaq”) of the anticipated consummation of the Merger and (ii) requested that Nasdaq (x) suspend trading of the Shares, effective at 8:00 p.m., Eastern Time, on May 13, 2026, and, following the Effective Time, (y) file with the U.S. Securities and Exchange Commission (the “SEC”) a Form 25, Notification of Removal from Listing…
Termination of a Material Definitive Agreement In connection with the consummation of the Merger, effective as of immediately prior to the Effective Time, the Company terminated its 2017 Employee Stock Purchase Plan. In connection with the consummation of the Merger, and concurrently with the Effective Time, the Company terminated all commitments outstanding under, and repaid all outstanding loans and other amounts due under, the Financing Agreement, dated as of June 30, 2025 (and as further…
Changes in Control of Registrant. As a result of the consummation of the Offer and the Merger, on May 14, 2026, a change in control of the Company occurred, and the Company is now a wholly owned subsidiary of Biogen. The information set forth in the Introductory Note, Item 2.01,
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of the Effective Time, Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof. These resignations were tende…
Completion of Acquisition or Disposition of Assets. The information set forth in the Introductory Note and
Material Modification to Rights of Security Holders. The information set forth in the Introductory Note, Item 3.01,
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 28, 2026, the compensation committee of the board of directors of Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) approved an amendment and restatement of the Apellis Pharmaceuticals, Inc. Executive Separation Benefits and Retention Plan (the “A&R Separation Benefits Plan”), in connection with the transactions contemp…
Other Events. Press Release On March 31, 2026, the Company and Parent issued a joint press release announcing the entry into the Merger Agreement. A copy of the press release is attached as Exhibit 99.2 hereto and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking” statements that are subject to risks, uncertainties and other factors relating to future events and the future performance of Biogen I…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 30, 2026, the compensation committee of the Company Board approved the Apellis Pharmaceuticals, Inc. Excise Tax Gross-Up Plan (the “Plan”), which provides that “disqualified individuals” of the Company within the meaning of Section 280G of the Internal Revenue Code (including the Company’s named executive officers) may become participants…
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, Pur…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 27, 2026, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Mikael Dolsten, M.D., Ph.D., to the Board as a Class I director, effective as of March 1, 2026, to serve until the Annual Meeting of Stockholder…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.